Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Pulmonary administered anticholinergic agents have shown their importance in the chronic
obstructive pulmonary disease (COPD) management to reduce morbidity, disability and
mortality. To date, the recommended treatment of moderate to severe COPD patients consist in
the combination of ß2 agonist and long acting antimuscarinic compounds. There is still a
medical need in new product that could exhibit both anti-inflammatory and strong
bronchodilation potency. V0162 is a compound with a potent anticholinergic activity.
Secondary PD properties of V0162 could enhance the efficacy of this antimuscarinic compound
and could bring new option in the treatment of this life-threatening disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pierre Fabre Medicament
Collaborators:
SGS Life Sciences SGS Life Sciences, a division of SGS Belgium NV